T3D Therapeutics announced it has been awarded a competitive $250,000 Strategic Research Loan (SRL) from the North Carolina Biotechnology Center. The SRL Program funds research to advance development of commercially viable technologies/products. Through the SRL program, loans of up to $250,000 are available for life science companies in North Carolina. This program supports companies in reaching specific and meaningful research milestones that would position them to obtain additional funding from private and public sources.
Recent Posts
- T3D Therapeutics Selected to Present Topline Results from the Phase 2 PIONEER Study of T3D-959 as Late Breaking News at the 16th Clinical Trials on Alzheimer’s Disease Conference (CTAD)
- T3D Therapeutics, Inc.: T3D Therapeutics Announces First Patient Dosed in its Phase 2 Study of T3D-959 for the Treatment of Mild to Moderate Alzheimer’s Disease
- T3D Therapeutics Receives a Research Award from the Alzheimer’s Association Part the Cloud-Gates Partnership Grant Program
- Alzheimer’s Association Part The Cloud Grant Program Invests $24 Million in 16 Innovative Research Trials
- Leading Alzheimer’s Disease Experts Join T3D Therapeutics’ Scientific Advisory Board